19962744

Source:http://linkedlifedata.com/resource/pubmed/id/19962744

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0002092, umls-concept:C0004827, umls-concept:C0007450, umls-concept:C0024880, umls-concept:C0442118, umls-concept:C0805586, umls-concept:C0871261, umls-concept:C0966225, umls-concept:C1280500, umls-concept:C1704632, umls-concept:C1706817, umls-concept:C2911692
pubmed:issue	4
pubmed:dateCreated	2010-4-7
pubmed:abstractText	Omalizumab treatment suppresses FcepsilonRI expression faster on blood basophils than skin mast cells.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/U19 AI070345-01, http://linkedlifedata.com/resource/pubmed/grant/U19 AI070345-010002, http://linkedlifedata.com/resource/pubmed/grant/U19 AI070345-018022, http://linkedlifedata.com/resource/pubmed/grant/U19 AI070345-02, http://linkedlifedata.com/resource/pubmed/grant/U19 AI070345-020002, http://linkedlifedata.com/resource/pubmed/grant/U19 AI070345-03, http://linkedlifedata.com/resource/pubmed/grant/U19 AI070345-030002
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/19962744-10228046, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962744-11344350, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962744-11704611, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962744-14767445, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962744-15065831, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962744-15356552, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962744-15478383, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962744-15746882, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962744-1607547, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962744-16159624, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962744-16790701, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962744-17125820, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962744-18087163, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962744-19039320, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962744-19130932, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962744-2582257, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962744-3349590, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962744-6190920, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962744-8360482, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962744-9013989
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/1275002
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Allergens, http://linkedlifedata.com/resource/pubmed/chemical/Anti-Allergic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Anti-Idiotypic, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, IgE, http://linkedlifedata.com/resource/pubmed/chemical/omalizumab
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	1097-6825
pubmed:author	pubmed-author:AlexanderValV, pubmed-author:BochnerBruce SBS, pubmed-author:EckmanJohn AJA, pubmed-author:KellyDeniseD, pubmed-author:LiuMark CMC, pubmed-author:MacglashanDonald WDWJr, pubmed-author:SainiSarbjit SSS, pubmed-author:SterbaPatricia MPM
pubmed:copyrightInfo	Copyright (c) 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
pubmed:issnType	Electronic
pubmed:volume	125
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	889-895.e7
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:19962744-Adult, pubmed-meshheading:19962744-Allergens, pubmed-meshheading:19962744-Animals, pubmed-meshheading:19962744-Anti-Allergic Agents, pubmed-meshheading:19962744-Antibodies, Anti-Idiotypic, pubmed-meshheading:19962744-Antibodies, Monoclonal, pubmed-meshheading:19962744-Antibodies, Monoclonal, Humanized, pubmed-meshheading:19962744-Basophils, pubmed-meshheading:19962744-Cats, pubmed-meshheading:19962744-Double-Blind Method, pubmed-meshheading:19962744-Female, pubmed-meshheading:19962744-Histamine Release, pubmed-meshheading:19962744-Humans, pubmed-meshheading:19962744-Hypersensitivity, pubmed-meshheading:19962744-Male, pubmed-meshheading:19962744-Mast Cells, pubmed-meshheading:19962744-Middle Aged, pubmed-meshheading:19962744-Nasal Provocation Tests, pubmed-meshheading:19962744-Receptors, IgE, pubmed-meshheading:19962744-Skin Tests, pubmed-meshheading:19962744-Young Adult
pubmed:year	2010
pubmed:articleTitle	Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge.
pubmed:affiliation	Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Md, USA.
pubmed:publicationType	Journal Article, Randomized Controlled Trial